$123.04
0.64% today
Nasdaq, Sep 16, 08:17 pm CET
ISIN
US64125C1099
Symbol
NBIX
Sector
Industry

Neurocrine Biosciences, Inc. Stock price

$122.25
-28.45 18.88% 1M
-19.55 13.79% 6M
-9.51 7.22% YTD
+7.95 6.96% 1Y
+25.55 26.42% 3Y
+25.84 26.80% 5Y
+106.68 685.16% 10Y
Nasdaq, Closing price Fri, Sep 13 2024
+0.97 0.80%
ISIN
US64125C1099
Symbol
NBIX
Sector
Industry

Key metrics

Market capitalization $12.34b
Enterprise Value $11.60b
P/E (TTM) P/E ratio 36.93
EV/FCF (TTM) EV/FCF 23.45
EV/Sales (TTM) EV/Sales 5.47
P/S ratio (TTM) P/S ratio 5.82
P/B ratio (TTM) P/B ratio 4.92
Revenue growth (TTM) Revenue growth 26.69%
Revenue (TTM) Revenue $2.12b
EBIT (operating result TTM) EBIT $544.70m
Free Cash Flow (TTM) Free Cash Flow $494.60m
Cash position $1.04b
EPS (TTM) EPS $3.31
P/E forward 24.83
P/S forward 5.30
EV/Sales forward 4.98
Short interest 2.48%
Show more

Is Neurocrine Biosciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.

Neurocrine Biosciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a Neurocrine Biosciences, Inc. forecast:

24x Buy
86%
4x Hold
14%

Analyst Opinions

28 Analysts have issued a Neurocrine Biosciences, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Neurocrine Biosciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '23
+/-
%
1,887 1,887
27% 27%
100%
- Direct Costs 58 58
50% 50%
3%
1,830 1,830
26% 26%
97%
- Selling and Administrative Expenses 866 866
18% 18%
46%
- Research and Development Expense 547 547
22% 22%
29%
416 416
56% 56%
22%
- Depreciation and Amortization 21 21
37% 37%
1%
EBIT (Operating Income) EBIT 395 395
57% 57%
21%
Net Profit 250 250
62% 62%
13%

In millions USD.

Don't miss a Thing! We will send you all news about Neurocrine Biosciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Neurocrine Biosciences, Inc. Stock News

Negative
Reuters
4 days ago
Neurocrine Biosciences said its experimental drug did not achieve the primary goal in a mid-stage trial aimed at improving cognitive function in patients with schizophrenia.
Neutral
PRNewsWire
4 days ago
Second Phase 2 Study for Luvadaxistat Fails to Meet Primary Endpoint as Potential Treatment for Cognitive Impairment Associated with Schizophrenia Results Confounded by Variability in Cognition Measures Across Population Studied and Potential Imbalance in Baseline Characteristics of Enrolled Subjects Neurocrine Biosciences to Focus Resources on Phase 3 Clinical Development of NBI-1117568 for Sc...
Neutral
PRNewsWire
6 days ago
SAN DIEGO , Sept. 10, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the 2024 Cantor Global Healthcare Conference in New York at 3:05 p.m.
More Neurocrine Biosciences, Inc. News

Company Profile

Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.

Head office United States
CEO Kevin Gorman
Employees 1,400
Founded 1992
Website www.neurocrine.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today